We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other ...

Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if ...

Silence Therapeutics PLC Sponsored ADR (SLN) closed the last trading session at $5.14, gaining 68.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) ...

Silence Therapeutics Plc SLN reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, according ...

Silence Therapeutics plc's Zerlasiran showed significant Lp(a) reduction but was overshadowed by Eli Lilly's oral Muvalaplin, which offers similar efficacy with easier administration and potentially ...

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

SLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has decreased $0.15 since the market last closed. This is a 2.23% ...

Women with endometrial cancer who are found to have lymph-node-positive disease during surgical staging by lymphadenectomy benefit from adjuvant chemotherapy; however, the remaining 78% of women who ...